We demonstrate that combination treatment caused irreversible cell cycle arrest, increased apoptosis, reduced cell division and survival of CD34+ cells in CML compared to normal cells, with CML-iPSCs displaying less self-renewing potential and enhanced differentiation following therapy. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.